Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results Nature.com Nawigacja wpisu Doctors Are Leaving Academic Medicine. Most Of Them Are Female – Forbes Three MS therapies listed as WHO essential medicines | Multiple… – Multiple Sclerosis News Today
